Form 4: Vaxart Director David Wheadon Reports Significant Equity and Option Grants

Vaxart, Inc. Director David E. Wheadon has reported the acquisition of 16,000 shares of common stock from restricted stock unit vesting and a grant of 95,400 stock options, signaling an increase in his beneficial ownership.

Summary

• David E. Wheadon, a Director of Vaxart, Inc. (VXRT), reported changes in his beneficial ownership of company securities through a Form 4 filing.
• On June 13, 2025, Mr. Wheadon acquired 16,000 shares of Vaxart common stock through the vesting of restricted stock units. These shares were granted at a price of $0.
• Following this transaction, Mr. Wheadon's direct beneficial ownership of common stock increased to 46,750 shares.
• Additionally, on June 13, 2025, Mr. Wheadon was granted 95,400 stock options with an exercise price of $0.7 per share. These options were granted at a price of $0.
• The shares underlying both the restricted stock units and the stock options are set to vest on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026, which is the first anniversary of the grant date.
• The stock options have an expiration date of June 13, 2035.
• An accompanying Exhibit 24 details a Power of Attorney granted by David Wheadon on March 5, 2025, authorizing specific individuals to execute and file Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director increasing their stake (even through grants) can be seen as a sign of confidence in the company's future. It's a routine compensation event, so not highly impactful, but generally viewed favorably.

Positives

• Director David E. Wheadon increased his beneficial ownership in Vaxart, Inc. through the acquisition of 16,000 common shares and a grant of 95,400 stock options, which can be interpreted as a sign of confidence in the company's future.
• The equity grants align the director's long-term interests with those of shareholders through future vesting conditions.

Future Outlook

The vesting of the newly acquired restricted stock units and stock options is tied to future dates, specifically the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026, indicating a future milestone for the director's equity compensation.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common in the biotechnology and pharmaceutical industries where equity compensation is a standard practice for attracting and retaining key talent, including directors. It reflects the company's ongoing compensation strategy rather than a specific industry trend.

Corporate Governance

Related Party Transactions

• The acquisition of shares and grant of options to Director David E. Wheadon constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership, even through grants, may be viewed positively as it aligns management's interests with shareholder value.

Next Steps

• Vesting of 16,000 common shares and 95,400 stock options on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026.

Key Dates

Recommendation

Keywords

Vaxart, VXRT, SEC Form 4, Insider Transaction, Beneficial Ownership, Stock Options, Restricted Stock Units, Equity Grant, Director Compensation, Biotechnology, Pharmaceuticals